Join the Waiting List

See What’s Happening Inside Your Body, Now

For health-conscious individuals. Trusted by healthcare professionals.

Your step toward earlier investigation and more informed decisions.

How the Test Works

Science You Can Act On

MicroRNA-Powered. AI-Enhanced. Meaningful Insight.

Analyzes molecular signals linked to early-stage cancers, helping you and your physician decide if earlier follow-up is appropriate.

Download The Publications

It’s Not About Age, But About Stage

MicroRNA-Powered. AI-Enhanced. Meaningful Insight.

Analyzes molecular signals linked to early-stage cancers, helping you and your physician decide if earlier follow-up is appropriate.

Join the waiting list
l-dots

What Is the

miRoncol Test?

The Real-time Multi-Cancer Early Risk Assessment is a blood-based test that detects microRNA signatures – biological signals sometimes present in early-stage solid tumours.

It provides a snapshot of your current molecular cancer risk, empowering you to discuss results with your physician and decide whether further evaluation makes sense.

How It Works

The Science Behind It

Our approach combines:

m2

MicroRNA biomarkers

Highly sensitive indicators of early cellular change

m3

AI-based Pattern Recognition

Trained on human data

m4

Multi-Cancer Signatures

Designed to assess risk across common solid tumour types

Built on peer-reviewed research and informed by large-scale studies, miRoncol provides meaningful insights you and your doctor can act on together.

Download The Publications
l-dots

Who Should Consider This Test

  • Individuals with a family history of cancer
  • People with extended exposures to unhealthy lifestyle or environmental factors
  • Those investing in executive health or integrative medicine programs
  • Health-conscious individuals seeking proactive, prevention-first insight
Join the waiting list
Learn Who It’s For

Why Choose

miRoncol

  • Provides early cancer risk assessment at the molecular level
  • Offers meaningful insight to support physician-guided follow-up
  • Accessible and affordable
  • Complements established cancer screening programs
Start Your Risk Assessment
l-dots

Cancer Types Covered

miRoncol’s Real-time Multi-Cancer Early Risk Assessment is designed to identify molecular patterns linked to more than a dozen common solid tumours. Together, these cancers represent about 80% of cancer incidence in men and 40% in women in Canada.

  • Lung
  • Colorectal
  • Prostate
  • Pancreatic
  • Gastric
  • Ovarian
  • Liver & biliary tract
  • Bladder
  • Sarcoma
  • Glioma

This coverage represents the majority of cancers that impact Canadians today. While not diagnostic, miRoncol provides a meaningful pre-screen that complements existing screening programs.

l-dots

For Partners

Supporting Clinicians, Executive Health Teams & Preventive Care Professionals. miRoncol works with:

We help you connect to:

  • Family doctors and integrative medicine practitioners
  • Executive health, longevity, and wellness clinics
  • Naturopathic practitioners
  • Select health coaches and wellness professionals

Our test offers a molecular pre-screen that can be incorporated into annual checkups, preventive health packages

Join Our Partner Program